The Department of Defense (DOD) is offering the Amyotrophic Lateral Sclerosis (ALS) Clinical Biomarker Development Award to advance biomarker development for enriching ALS clinical trials. This grant is for projects focusing on biomarkers relevant to specific therapies, therapeutic classes, or particular ALS subtypes. A crucial component is detailing the biomarker category and its intended context of use in ALS therapeutic development, including regulatory considerations for clinical trials or practice. Suitable studies include linking patient biosamples to molecular data, analyzing biospecimens alongside clinical trials, correlating trial data with outcomes, and developing strategies to measure disease progression, such as digital biomarkers. This initiative aims to enhance the precision and effectiveness of ALS research.
Opportunity ID: 345881
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | HT9425-23-ALSRP-CBDA |
| Funding Opportunity Title: | DOD Amyotrophic Lateral Sclerosis, Clinical Biomarker Development Award |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement Grant |
| Category of Funding Activity: | Science and Technology and other Research and Development |
| Category Explanation: | – |
| Expected Number of Awards: | 10 |
| Assistance Listings: | 12.420 — Military Medical Research and Development |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Feb 08, 2023 |
| Last Updated Date: | Feb 08, 2023 |
| Original Closing Date for Applications: | Jul 13, 2023 |
| Current Closing Date for Applications: | Jul 13, 2023 |
| Archive Date: | Aug 12, 2023 |
| Estimated Total Program Funding: | $7,200,000 |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled “Additional Information on Eligibility” |
| Additional Information on Eligibility: | – |
Additional Information
| Agency Name: | Dept. of the Army — USAMRAA |
| Description: |
The intent of the FY23 ALSRP Clinical Biomarker Development Award is to support the development of biomarkers to enrich clinical trials in Amyotrophic Lateral Sclerosis (ALS). Biomarker development projects can be relevant to a specific therapy, a class of therapeutics, or to a specific ALS subtype (such as a particular genetic mutation) and do not have to broadly apply to all patients. A description of the biomarker category and intended context of use (COU) in ALS therapeutic development, including regulatory considerations for use in ALS clinical trials or clinical practice, is an important component. Examples of studies appropriate for submission to the FY23 ALSRP Clinical Biomarker Development Award include, but are not limited to:
|
| Link to Additional Information: | – |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
CDMRP Help Desk
Phone: 301-682-5507 Email: help@eBRAP.org Email:help@eBRAP.org |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 345881 Full Announcement-FY23 ALSRP CBDA -> HT9425-23-ALSRP-CBDA_PA_GG.pdf
Packages
| Agency Contact Information: | CDMRP Help Desk Phone: 301-682-5507 Email: help@eBRAP.org Email: help@eBRAP.org |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| 12.420 | PKG00279749 | Feb 08, 2023 | Jul 13, 2023 | View |
Package 1
Mandatory forms
345881 RR_SF424_5_0-5.0.pdf
345881 AttachmentForm_1_2-1.2.pdf
345881 RR_PersonalData_1_2-1.2.pdf
345881 RR_KeyPersonExpanded_4_0-4.0.pdf
345881 RR_Budget_3_0-3.0.pdf
345881 PerformanceSite_4_0-4.0.pdf
Optional forms
345881 RR_SubawardBudget30_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
